Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L36a pseudogene 18 (RPL36AP18) is a processed pseudogene in the human genome[10]. It shares high sequence similarity with the protein-coding gene ribosomal protein L36a (RPL36A), which encodes a structural component of the 60S ribosomal subunit[3][7][10]. However, RPL36AP18 does not encode a functional protein[10]. Like many pseudogenes, it is unlikely to possess significant biological or therapeutic relevance. It is not considered a drug target, nor does it participate in known cellular pathways, molecular functions, or disease processes[10]. Key context: - Pseudogenes such as RPL36AP18 arise from gene duplication or retrotransposition events involving functional genes (here, RPL36A), but they typically accumulate mutations rendering them nonfunctional[3][10]. - While some pseudogenes may exert regulatory roles at the RNA level in rare cases, there is no evidence that RPL36AP18 is functional or relevant in molecular pharmacology or therapeutics[10]. This entry should *not* be treated as a valid therapeutic target in drug discovery or biomedical research contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L36a pseudogene 18 (RPL36AP18).